

ACTION REQUEST

Subject: Subcontract Agreement between the University of Michigan and SubLambda Technologies, Inc.

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified while reviewing the Proposal Approval Form that then triggered a review of the project by the OVPR Conflict of Interest Review Committee. A plan for management of the possible risks associated with the conflicts of interest was then developed by the Committee and agreed to by the parties involved.

The proposed research agreement (Agreement) falls under the State of Michigan Conflict of Interest Statute because Dr. Alan J. Hunt is both an owner of SubLambda Technologies, Inc. and an employee of the University. The law permits such an Agreement provided it is disclosed to the executive officers and approved in advance by a 2/3 vote of the Regents of the University of Michigan.

Background:

Dr. Alan J. Hunt, Associate Professor of Biomedical Engineering in the College of Engineering, and Assistant Research Scientist at the Institute of Gerontology, is part owner of a for-profit company, SubLambda Technologies, Inc. SubLambda has received an NIH STTR award and now wishes to enter into a subcontract to the University so that a portion of the research described in the award's proposal is performed by the University under the direction of Dr. Hunt.

Nature of the Project:

The Company has applied for and received funding from the National Institutes of Health (NIH) under the Small Business Technology Transfer (STTR) solicitation. This proposed project will constitute a subcontract to the University in order to provide services under SubLambda's grant. Dr. Hunt's participation in this project will only be in his capacity as an employee of the University.

Agreement Terms:

The terms of the Agreement conform to University policy. Dr. Hunt will be the Principal Investigator for the project at the University to be conducted over an initial one-year period at an estimated total cost of \$48,838 including indirect cost at 0%, the rate that is available to all STTR Phase I proposals.


Impact of the Agreement:

The Agreement enables research to be performed to develop compact immunoassay devices for clinical diagnostics and biochemical analysis, which may reduce the need for laboratory and highly trained personnel, reduce required sample sizes and reagent volumes, and result in significant cost savings, and faster results compared with most existing immunoassays. It also provides for ongoing support and collaboration between the College of Engineering and a start-up company.

Recommendation:

This matter has been reviewed and approved by the OVPR Conflict of Interest Review Committee and by the Associate Dean for Research of the College of Engineering. In light of the disclosure made in this document and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the University of Michigan Regents approve of the University entering into this Agreement with SubLambda, Inc.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Stephen R. Forrest".

Stephen R. Forrest
Vice President for Research

April 2006